Boston Scientific CRM In 2010: Steep Challenges, Some Prospects
This article was originally published in The Gray Sheet
Executive Summary
Sales force firings and perceived product design issues are adding to an already challenging cardiac rhythm management picture for Boston Scientific in 2010
You may also be interested in...
Boston Sci, St. Jude Face New Federal Inquiries From OIG, DOJ
The two firms’ cardiac devices businesses are facing more scrutiny from the federal government. Boston Scientific is facing an inquiry from the HHS Office of Inspector General, and St. Jude from the Department of Justice.
Boston Scientific Recalls All Implantable Defibrillators, Suspends Sales
Boston Scientific is recalling all lines of its implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators nationwide because the firm made manufacturing process changes without proper FDA approval
Boston Scientific Recalls All Implantable Defibrillators, Suspends Sales
Boston Scientific is recalling all lines of its implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators nationwide because the firm made manufacturing process changes without proper FDA approval